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Abstract
Mammary serine protease inhibitor (maspin) is an important tumor suppressor gene whose 
expression is associated not only with tumor growth inhibition but also with decreased 
angiogenesis and metastasis. Maspin expression is down-regulated in metastatic tumors by 
epigenetic mechanisms, including aberrant promoter hypermethylation. We have constructed 
artificial transcription factors (ATFs) as novel therapeutic effectors able to bind 18-bp sites in the 
maspin promoter and reactivate maspin expression in cell lines that harbor an epigenetically 
silenced promoter. In this article, we have investigated the influence of epigenetic modifications 
on ATF-mediated regulation of maspin by challenging MDA-MB-231 breast cancer cells, 
comprising a methylated maspin promoter, with different doses of ATFs and chromatin 
remodeling drugs: the methyltransferase inhibitor 5-aza-2′-deoxycytidine and the histone 
deacetylase inhibitor suberoylanilide hydroxamic acid. We found that the ATFs synergized with 
both inhibitors in reactivating endogenous maspin expression. The strongest synergy was observed 
with the triple treatment ATF-126 + 5-aza-2′-deoxycytidine + suberoylanilide hydroxamic acid, in 
which the tumor suppressor was reactivated by 600-fold. Furthermore, this combination inhibited 
tumor cell proliferation by 95%. Our data suggest that ATFs enhance the efficiency of chromatin 
remodeling drugs in reactivating silenced tumor suppressors. Our results document the power of a 
novel therapeutic approach that combines both epigenetic and genetic (sequence-specific ATFs) 
strategies to reactivate specifically silenced regions of the genome and reprogram cellular 
phenotypes.
Introduction
Tumor suppressor genes play an essential role in controlling unscheduled cell proliferation 
and they act as gatekeepers that block neoplastic processes in tissues. Due to the pivotal role 
of tumor suppressor gene inactivation during tumor progression, these genes are primary 
Copyright © 2008 American Association for Cancer Research.
Requests for reprints: Pilar Blancafort, Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of 
North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365. Phone: 919-966-1614. pilar_blancafort@med.unc.edu. 
HHS Public Access
Author manuscript
Mol Cancer Ther. Author manuscript; available in PMC 2015 May 04.
Published in final edited form as:













targets in cancer therapeutics. Inactivation can occur via a variety of mechanisms, such as 
point mutations, deletions, and epigenetic modifications (1–3). Epigenetic modifications, 
such as DNA and histone methylation and histone deacetylation, result in a compact 
chromatin configuration that silences entire DNA regions (1–6). At the promoter level, this 
compact chromatin topology restricts the physical access of the polymerase II complex to 
regulatory sequence domains, resulting in inhibition of tumor suppressor transcription (7–9). 
Unlike genetic alterations, which irreversibly inactivate tumor suppression expression, 
epigenetic modifications are potentially reversible (9–11).
The reversible nature of epigenetic silencing offers a unique opportunity for therapeutic 
intervention by reactivating endogenous tumor suppressor genes. Several chromatin 
remodeling drugs have been developed to release the repressed state of tumor suppressor 
genes. These drugs act by inhibiting DNA methyltransferases or histone deacetylases 
(HDAC), resulting in increased promoter accessibility and enhanced tumor suppressor gene 
transcription (12 – 14). To date, the most widely used chromatin remodeling drug is the 
DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (5-aza-2′-dC), recently approved 
for therapeutic treatment (15). Several methyltransferase inhibitors [such as 5-aza-dC and 
MG98 (16, 17)] and HDAC inhibitors [such as suberoylanilide hydroxamic acid (SAHA; 
ref. 18), valproic acid (19), and pivaloyloxymethyl butyrate (20, 21)] are presently in phase I 
and II clinical trials. The small-molecule inhibitors 5-aza-2′-dC and SAHA have been used 
to reactivate tumor suppressor genes aberrantly methylated in aggressive tumor cells, such 
as desmocollin 3 (22), gelsolin (23), and mammary serine protease inhibitor (maspin; refs. 
13, 22). Moreover, several reports have shown that methyltransferase and HDAC inhibitors 
are able to synergize to reactivate tumor suppressor expression (24, 25). Nevertheless, 
potential limitations for the use of these drugs in cancer patients include their toxicity, lack 
of target specificity, and development of acquired drug resistance (6, 26). Thus, there is a 
need for the development of novel strategies to increase the targeted efficiency and 
specificity of current anticancer drugs.
Our laboratory has recently applied a new strategy to specifically reactivate tumor 
suppressor genes silenced by epigenetic mechanisms in aggressive tumors (27). We have 
targeted the tumor suppressor gene maspin using three rationally designed artificial 
transcription factors (ATFs). These ATFs comprise six sequence-specific zinc finger (ZF) 
domains, designed to recognize unique 18-bp sites in the maspin promoter. The ZFs were 
linked to the VP64 activator domain, which mediates promoter up-regulation. We found that 
the capability of the ATFs to up-regulate maspin depended on the cell line analyzed, 
indicating that the structure of the chromatin can influence ATF-mediated transactivation of 
maspin. In the aggressive MDA-MB-231 breast cancer cell line, which comprises a 
methylated and silenced maspin promoter, only one ATF (ATF-126) was able to partially 
reactivate the endogenous maspin. We hypothesized that the structure of the chromatin 
(which is found in a more compact configuration in methylated promoters) could act as a 
partial blockade and restrict ATF-mediated transactivation of maspin. In this article, we 
have investigated the influence of chromatin structure at the maspin promoter in the context 
of artificial ATF regulation by challenging MDA-MB-231 cells expressing ATF-126 with 
different doses of 5-aza-2′-dC and SAHA. We found that ATF synergized with both 
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inhibitors to reactivate maspin expression. The strongest synergy was observed with the 
triple treatment ATF-126 + 5-aza-2′-dC + SAHA, in which the tumor suppressor was 
reactivated by 600-fold. Furthermore, this combination inhibited breast tumor cell 
proliferation by 95%. Our data suggest that ATFs amplify the response of chromatin 
remodeling drugs in reactivating silenced tumor suppressors. Thus, combinations of low 
concentrations of chromatin remodeling drugs and sequence-specific ATFs are efficient in 
reactivating silenced regions of the genome and effectively reprogram cellular phenotypes. 
This could represent a powerful therapeutic strategy to target a variety of neoplasias through 
specific reactivation of tumor suppressor genes.
Materials and Methods
Cell Lines
MDA-MB-231 breast carcinoma, MDA-MB-468, MCF-12A, and 293TGagPol cell lines 
were obtained from the American Type Culture Collection.
Sodium Bisulfite Genomic Sequencing of the Maspin Promoter
Genomic DNA (1.5 μg) was modified with sodium bisulfite using EZ DNA Methylation-
Gold kit (Zymo Research). The maspin promoter was amplified from the bisulfite-modified 
DNA by PCR using primers specific to the bisulfite-modified sequence of the maspin 
promoter: 5′-TAGGATTTTAAAAAGAAATTTTTTG-3′(forward primer) and 5′-
CCCACCTTACTTACCTAAAATCACA-3′(reverse primer). The PCR products were 
cloned and 10 positive recombinants were sequenced. The methylation status of individual 
CpG sites was determined by comparison of the sequence obtained with the known maspin 
sequence.
ATF Retroviral Transduction
The retroviral vector pMX-6ZFs-VP64-IRES-GFP (28) was first cotransfected with a 
plasmid (pMDG.1) expressing the vesicular stomatitis virus envelope protein into 293TGag-
Pol cells to produce retroviral particles. Transfection was done using Lipofectamine as 
recommended (Invitrogen). The viral supernatant was used to infect the host cell lines, and 
the infection efficiency was assessed by flow cytometry (FACSCalibur, BD Biosciences) 
using green fluorescent protein as marker.
Drug Treatments
ATF-transduced cells and control cells (0.25 × 106 untransduced cells, cells transduced with 
empty retroviral vector, and a control ATF that does not regulate maspin) were seeded in 10-
cm tissue culture plates. These samples were treated with different concentrations of 5-
aza-2′-dC (0, 0.025, 0.05, 0.125, 0.25, 0.625, 1.25, 2.5, 3.75, 6.25, 12.5, 25, 62.5, and 125 
μg/mL; Sigma) or SAHA (0, 0.0133, 0.026, 0.066, 0.132, 0.26, 0.4, 0.66, 1.32, 2.6, 3.97, and 
5.3 μg/mL; BioVision) or both inhibitors (5-aza-2′-dC and SAHA) during 48 h in a 37°C, 
5% CO2 incubator. Cells were collected, and the RNA was extracted, reverse transcribed, 
and processed for real-time quantification of maspin.
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Real-time PCR Expression Assays
ATF-transduced cells and control cells, drug treated or nontreated, were collected, and the 
RNA was extracted and 2.5 μg were used for reverse transcription. Quantification of maspin 
and VP64 activator domain was obtained by real-time quantitative PCR using fluorescent 
Taqman assays (Applied Biosystems) as described (27). The primers and probes for the 
VP64 activator domain were the following: 5′-AAGCGACGCATTGGATGAC-3′(forward 
primer), 5′-GGAACGTCGTACGGGTAGTTAATT3′(reverse primer), and 5′-6FAM-
TCGGCTCCGATGCT-MGBNFQ-3′(probe). Real-time PCR data were analyzed using the 
comparative 2−ΔΔCT method (SDS 2.1 RQ software, Applied Biosystems) and results were 
expressed as “fold change” in maspin RNA expression normalized to GAPDH and relative 
to the vehicle-treated control (29).
Proliferation Assays
Proliferation assays were done measuring cell viability determined by a survival assay 
(XTT, Roche, according to the manufacturer’s instructions). To measure the effect of 
ATF-126, 5-aza-2′-dC, and SAHA in cell viability, MDA-MB-231 breast cancer cells were 
transduced with different concentrations of ATF-126 plasmid or/and treated with 5-aza-2′-
dC or SAHA (same concentration described earlier). Twenty-four hours after transfection, 
3,000 cells per well (5 wells per concentration) were seeded into 96-well format tissue 
culture plates. Cell viability was measured using the XTT assay by monitoring the 
absorbance (405 nm) of the cells at 0 and 72 h after transduction and 48 h of drug treatment.
Experimental Drug Dose-Effect Plots
Dose-effect curves and median-effect plots were generated for each set of the real-time and 
proliferation data samples using the software package PharmToolsPro (McCary Group; ref. 
30). The median-effect dose (Dm50) and the slope (m) were calculated from the median-
effect plots and introduced in the isobologram equation for the calculation of the CI (28, 31–
33). The CI isobologram equation [CI = (D)1/(Dx)1 + (D)2/(Dx)2 + (D)3/(Dx)3] was used for 
data analysis of three-drug combination (31, 32). CI < 1, CI = 1, and CI > 1 indicate 
synergy, additive effect, and antagonism, respectively.
Statistical Analysis
Real-time PCR and viability experiments were repeated thrice using three independently 
processed samples. For each sample, we did triplicate acquisitions. Differences between all 
treatments were analyzed by the ANOVA test with a critical level of significance set up at P 
< 0.05, and significant differences between groups of treatments were analyzed with post 
hoc Turkish test using the software GraphPad Prism v.5.
Results
ATFs Reactivate Maspin in Combination with 5-Aza-2′-dC and SAHA
In a previous report, we have described the construction of three ATFs designed to bind 18-
bp sites in the maspin proximal promoter (27). The ATFs were constructed by linkage of six 
sequence-specific ZF domains with the VP64 transactivator domain (Fig. 1A). Each ZF is a 
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compact 30-amino acid domain composed of a recognition α-helix packed with two 
antiparallel β-strands via the coordination of a zinc ion. The α-helix of each ZF specifically 
recognizes 3 bp in the DNA or “recognition triplet.” The main contact positions are residue 
+6 of the recognition helix, which interacts with the 5′nucleotide position of the triplet, 
residue +3, interacting with the middle base, and position −1, which makes H-bonding 
contacts with the 3′nucleotide of the triplet (34).
Our previous results show that the efficiency of maspin activation by ATFs depended on the 
particular cell line analyzed, indicating that the structure of the chromatin may influence the 
ATF-mediated regulation of the endogenous promoter. To investigate the influence of 
promoter topology in ATF regulation, we focused our studies on the MDA-MB-231 cell 
line, an aggressive cell estrogen receptor–negative breast cancer cell line that comprises a 
methylated and silenced maspin promoter (35). First, we verified the methylation status of 
the maspin promoter in the MDA-MB-231 background by doing sodium bisulfate 
sequencing of the maspin proximal promoter and we mapped the ATF-binding sites in this 
sequence. As shown in Fig. 1B, the ATF-126–binding site contained two methylated 
cytosines, whereas the ATF-97–binding site comprised one methylated cytosine. In contrast, 
both ATF-452–binding and the two p53-binding sites in the maspin promoter mapped in 
methylation-free regions. The same methylation pattern was found in other aggressive 
cancer cell lines comprising a silenced maspin promoter (data not shown). The ATF-binding 
sites were not found mutated or deleted in all 10 genomic clones processed by sequencing. 
This agrees with previous reports (35–37), which showed that maspin gene is not found 
mutated or deleted in tumor cells, but its promoter is silenced by epigenetic mechanisms. 
Consistent with this epigenetic silencing, we found that MDA-MB-231 cells have no 
detectable maspin protein as assessed by Western blotting (Fig. 2C). When retrovirally 
transduced in MDA-MB-231 cells, only the ATF-126 was able to strongly reactivate the 
promoter (70-fold relative to controls, in the absence of drugs), whereas ATF-97 and 
ATF-452 alone had a much weaker activity (27).
To investigate the influence of methylation and chromatin structure on ATF regulation, we 
challenged ATF-expressing cells with 5-aza-2′-dC and SAHA (Fig. 2). These drugs are 
known to induce a more relaxed promoter topology, which facilitates the access of 
transcription factors and DNA polymerase complex (7, 8, 38). 5-Aza-2′-dC causes inhibition 
of DNA methyltransferase activity. The DNA methyltransferase is bound irreversible to the 
DNA through the 5-aza-2′-dC residues, which results in a depletion of soluble DNA 
methyltransferase protein levels. The lack of DNA methyltransferase availability leads to a 
DNA replication with global demethylation (22, 39–41). SAHA interacts with HDAC 
enzymes at the catalytic site inhibiting their activity. This process leads to histone 
acetylation, which opens the chromatin structure, increasing transcriptional activity (42, 43). 
We hypothesized that remodeling the chromatin in the MDA-MB-231 cell line toward a 
more open configuration facilitated by 5-aza-2′-dC or/and SAHA enhances the efficiency of 
ATF regulation of maspin. To test this hypothesis, we first retrovirally transduced ATF-97, 
ATF-126, and ATF-452 into MDA-MB-231 cells. Additionally, cells were transduced with 
a control empty retroviral vector (control) and with a retroviral vector lacking the ZF 
domains (pMXVP64SS). These samples were treated with 5-aza-2′-dC (5 μg/mL) or SAHA 
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(0.5 μg/mL) or both inhibitors (5 and 0.5 μg/mL) and processed by real-time PCR for 
quantification of maspin mRNA levels. These concentrations were chosen in the range of 
the median-effect dose [Dm50, the concentration of inhibitor giving rise to 50% of maximum 
maspin mRNA up-regulation (31, 32, 44) calculated for these drugs (Fig. 3A–C)]. Maspin 
mRNA levels were calculated as a “fold change in mRNA expression” relative to the 
vehicle-treated MDA-MB-231 cell line as explained in Materials and Methods. Previously, 
we have found that in the absence of inhibitor only ATF-126 was able to strongly up-
regulate maspin compared with control cells (cells transduced with an empty retroviral 
vector), whereas ATF-97 and ATF-452 had a much weaker effect (27). To compare 
differences between treatments and to evaluate synergisms, we used an ANOVA test with a 
critical level of significance set up at P < 0.05. Significant differences between groups of 
treatments were analyzed with post hoc Turkish test.
As shown in Fig. 2A, particular ATFs synergized with chromatin remodeling drugs in 
reactivating maspin expression. ATF-452, which had a poor activity in up-regulating the 
promoter (3.2-fold), was not able to synergize with 5-aza-2′-dC, SAHA, or both inhibitions 
in up-regulating maspin expression. ATF-97 up-regulated maspin by 14-fold and synergized 
with both inhibitors when used separately: 5-aza-2′-dC (63-fold maspin up-regulation) and 
SAHA (156-fold). However, the triple treatment ATF-126 + 5-aza-2′-dC + SAHA did not 
significantly further improved regulation. ATF-126–transduced cells up-regulated maspin by 
70-fold. This ATF synergized with both inhibitors, 5-aza-2′-dC (161-fold) and SAHA (376-
fold), in reactivating maspin. In contrast with the other ATFs, the triple treatment ATF-126 
+ 5-aza-2′-dC + SAHA exhibited synergy, up-regulating maspin mRNA levels by 600-fold. 
This stimulatory effect leads to an 8.26-fold change in maspin mRNA expression relative to 
a breast cancer cell line carrying a nonmethylated promoter (the MDA-MB-468 cell line) 
and to ~40% of the expression levels observed in nontransformed breast epithelial cell lines, 
such as MCF-12A (Fig. 2B and C). In contrast with breast cancer cells, nontransformed 
breast epithelial cells express very high levels of maspin (37). Our data suggest that other 
epigenetic marks, in addition to methylation and histone acetylation, might contribute to 
maspin silencing in tumor cells.
Because the three ATFs target distinct 18-bp sites along the maspin promoter, their 
particular responses to the inhibitors could reflect local differences in methylation and/or 
acetylation levels in the chromatin. Overall, these experiments suggested that modifications 
of the chromatin leading to a more compact promoter topology could partially block or 
impair ATF regulation, probably by affecting ATF binding.
ATF-126 Synergizes with Low Concentrations of 5-Aza-2′dC and SAHA in Reactivating 
Maspin Expression
We subsequently focused our studies on ATF-126 because among all the ATFs analyzed it 
exhibited the strongest response in reactivating maspin in combination with chromatin 
remodeling drugs. High concentration or persistent exposure of tumor cells with chromatin 
remodeling drugs can potentially result in high toxicity (38, 45). Thus, novel approaches to 
reactivate tumor suppression expression while minimizing the exposure of tumor cells to the 
drugs are desired. We next investigated if synergy between the ATF and the chromatin 
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remodeling drugs was maintained when low concentrations of inhibitors (below their Dm50) 
were used. The Dm50 was calculated for each treatment, 5-aza-2′-dC, SAHA, and ATF-126, 
using dose-effect plots in the MDA-MB-231 breast cancer cell line (Fig. 3A–D). In these 
experiments, MDA-MB-231 cells were treated with different concentrations of 5-aza-2′-dC 
(0.025–125 μg/mL; Fig. 3A) or SAHA (0.07–5.3 μg/mL; Fig. 3B) during 48 h and maspin 
mRNA expression levels were monitored by real-time PCR assays. For ATF-126, cells were 
transduced with increasing concentrations of ATF-encoded DNA (0–1.3 μg/mL; Fig. 3C), 
and 72 h after transduction, cells were processed by real-time PCR to detect ATF-126 and 
maspin mRNA levels. The concentration of ATF-126 DNA used in the transfection 
correlated with ATF-126 mRNA levels detected in MDA-MB-231–transduced cells, as 
assessed by real-time PCR using ATF-specific primers (Fig. 3D). ATF-126 reactivated 
maspin in a concentration-dependent manner, reaching a maximum effect of 300-fold 
maspin mRNA relative to control cells, whereas 5-aza-2′-dC and SAHA induced a 
maximum of 13-fold maspin up-regulation relative to control cells. The dose-response plots 
were used to calculate the Dm50 for each single treatment. For ATF-126, the Dm50 (0.525 
μg/mL) was calculated as 50% maspin up-regulation at 72 h after transduction. For the 
inhibitors, the Dm50 was calculated as 50% maspin up-regulation after 48 h of drug 
treatment, being 5.55 and 0.75 μg/mL for 5-aza-2′dC and SAHA, respectively (Fig. 3A and 
B).
To study the synergy between ATF-126 and the chromatin remodeling drugs in reactivating 
maspin, we designed different drug combination experiments where the ATF-126 was used 
at its Dm50 and the inhibitors were used at their respective Dm50 (combination 1), 1/2Dm50 
(combination 2), and 1/3Dm50 (combination 3; Fig. 3F). As a control, MDA-MB-231 cells 
were subjected to single treatments (transduced with ATF-126 for 72 h or exposed to 5-
aza-2′-dC or SAHA for 48 h) and processed by real-time PCR to evaluate maspin mRNA 
levels. We additionally evaluated maspin mRNA levels for double and triple treatments 
using specific combinations of control cells, ATF-126–transduced cells, 5-aza-2′-dC, and 
SAHA (Fig. 3E). In all the combinations tested, we found that ATF-126 was able to 
synergize with 5-aza-2′-dC, SAHA, and both inhibitors to reactivate maspin. We found that 
the most effective combination in activating maspin was the triple treatment ATF-126 + 5-
aza-2′-dC + SAHA, with a 600-fold maspin up-regulation, when all the compounds were 
combined at their Dm50 (drug combination 1). Furthermore, ATF-126 synergized with 5-
aza-2′-dC and SAHA in reactivating maspin expression by 413-fold even using 1/3Dm50 of 
inhibitors (drug combination 3). No statistical difference was observed between combination 
2 (when 5-aza-2′-dC and SAHA were used at their 1/2Dm50) and combination 3 (when 5-
aza-2′-dC and SAHA were used at their 1/3Dm50). Overall, these results indicate that 
ATF-126 strongly synergized with a combination of methyltransferase and HDAC inhibitors 
to reactivate maspin expression and this synergism was maintained when low concentrations 
of inhibitors (below their Dm50) were used.
ATF-126 Synergizes with 5-Aza-2′dC and SAHA to Inhibit Tumor Cell Viability
Several reports showed that induction of maspin mRNA expression results in inhibition of 
tumor cell proliferation by enhancement of apoptosis. We next investigated if ATF-126 
could also synergize with 5-aza-2′-dC and SAHA in inducing inhibition of tumor cell 
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growth. MDA-MB-231 cells were transduced with a control vector or with ATF-126, and 72 
h after transduction, these cells were treated with 5-aza-2′-dC, SAHA, or both inhibitors 
during 48 h. Tumor cell viability was evaluated using survival assays {2,3-bis[2-methoxy-4-
nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT) assays}. The dose-
effect plots for ATF-126, 5-aza-2′-dC, and SAHA (Fig. 4A) were used to calculate the 
inhibitory concentration (IC50, the concentration of ATF-126 or inhibitor giving rise to 50% 
of inhibition of tumor cell growth at 72 h after transduction or after 48 h of drug treatment). 
The IC50 values were 0.15, 2.056, and 0.942 μg/mL for ATF-126, 5-aza-2′-dC, and SAHA, 
respectively. To evaluate synergisms, we applied a standard combinatorial method, which 
uses the isobologram equation to calculate the combinatorial index (CI). The interaction 
between drugs is defined as synergistic if CI < 1, antagonistic if CI > 1, and additive if CI = 
1 (Fig. 4B). Control-transduced or ATF-126–transduced cells were challenged with different 
concentrations of 5-aza-2′-dC, SAHA, or both inhibitors, as shown in Table 1. We used 
concentrations of ATF/5-aza-2′-dC/SAHA in the range of the IC50 value, which resulted on 
30% to 80% of tumor cell growth inhibition. As shown in Fig. 4B, ATF-126 synergized with 
5-aza-2′-dC, SAHA, and both inhibitors (5-aza-2′-dC + SAHA) for the majority of the drug 
combinations tested. The synergistic effect for the double treatments ATF-126 + 5-aza-2′-
dC, ATF-126 + SAHA, and 5-aza-2′-dC + SAHA was higher when low concentrations were 
used in each combination. For the triple treatment ATF-126 + 5-aza-2′-dC + SAHA, we 
observed a synergistic effect with all the combinations tested. The lowest (most synergistic) 
CI was achieved by the combination with the highest dose of ATF-126 and inhibitors, which 
results in 95% of inhibition of tumor cell viability compared with vehicle-treated control 
cells (Fig. 4C; doses are indicated in Table 1).
As shown in Fig. 4C, the triple treatment ATF-126 + 5-aza-2′-dC + SAHA was significantly 
the most efficient in decreasing tumor cell viability compared with all the other treatments. 
The double combinations ATF-126 + SAHA and ATF-126 + 5-aza-2′-dC reduced 
significantly cell viability compared with all the single treatments (ATF-126, 5-aza-2′-dC, 
and SAHA and vehicle; P = 0.05). However, our data in Fig. 4C did not reveal statistical 
differences between the following treatments: SAHA, 5-aza-2′-dC + SAHA, and ATF-126. 
The apparent discrepancy between the RNA and the viability data could be explained by the 
fact that these experiments measure different outcomes. Unlike real-time, which specifically 
measures maspin mRNA levels, cell viability is a complex phenotype involving many 
different gene products, including tumor suppressors such as maspin. The higher effect of 
SAHA and 5-aza-2′-dC observed in viability assays might suggest that these compounds 
reactivate many tumor suppressor genes, not just maspin (46, 47). Although off-target 
effects are possible with ATFs, these proteins have been engineered to reactivate specifically 
maspin and are not expected to regulate other tumor suppressor genes. We are presently 
investigating putative off-target effects of ATF-126.
To verify that the effect of the ATFs and inhibitors was specific for tumor cells and not 
normal epithelial cells, we did the same viability assays in a nontransformed breast epithelial 
cell line, the MCF-12A. In contrast with the MDA-MB-231 cell line, none of the 
combinations of ATFs and inhibitor was able to significantly up-regulate maspin expression 
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nor decrease cell viability as assessed by the ANOVA and post hoc Turkish tests 
(Supplementary Fig. S1).3
Discussion
In this article, we have investigated the influence of promoter structure in the regulation of 
the tumor suppressor gene maspin by ATFs. We have focused our analysis on the highly 
invasive, metastatic breast cancer cell line MDA-MB-231, which comprises a maspin 
promoter silenced by methylation and transcriptional repression (35), and on ATF-126, the 
strongest maspin regulator in this cell line (27). We have challenged MDA-MB-231 cells 
expressing ATF-126 with different doses of the methyltransferase inhibitor 5-aza-2′-dC and 
the HDAC1 inhibitor SAHA. These drugs interfere with repressive mechanisms, which 
maintain inaccessible chromatin structure: aberrant cytosine methylation and recruitment of 
HDAC complexes. Consequently, these inhibitors are able to relax the chromatin, 
facilitating access to the polymerase II transcriptional machinery (7 – 9). We hypothesized 
that disruption of the epigenetic silencing mediated by methyltransferase and HDAC 
inhibitors coupled to ATFs would result in an enhanced up-regulation of silenced genes. Our 
work shows that ATFs synergized with chromatin remodeling drugs to reactivate 
endogenous maspin expression. We found that maspin reactivation in response to the 
inhibitors depended on the ATF-binding site analyzed. It could be that, in the endogenous 
gene, these sites map in regions of the promoter that contain different levels of histone/
methylcytosine modifications. It is also possible that other endogenous factors, such as 
additional epigenetic marks in the nucleosome, the positioning of the nucleosomes, and 
CpG-binding proteins, could affect ATF binding and regulation. The strongest synergy was 
observed with a triple treatment (ATF-126 + 5-aza-2′-dC + SAHA), in which the tumor 
suppression was reactivated by 600-fold. Consistent with the tumor-suppressive functions of 
maspin, we found that this triple drug combination was also the most effective in inhibiting 
breast tumor cell proliferation in vitro.
A plausible model explaining this synergy is shown in Fig. 5. In a context of a silenced 
promoter, methylated CpG islands are associated with methyl-binding proteins, 
methyltransferases, and HDAC, which maintain the promoter in a compact configuration, 
inaccessible to the transcriptional machinery (4–6). Likewise, it is possible that in the 
context of a repressed maspin promoter the ATF-binding sites are not optimally accessible 
to the ATFs. In the ATF, the ZF domains are linked to the strong transactivator domain 
VP64, which recruits the mediator protein and other polymerase II–associated proteins 
(including chromatin remodeling enzymes and histone acetyltransferases), resulting in a 
partial maspin reactivation. The synergy between the ATF and the chromatin remodeling 
drugs could be explained by drug-induced enhanced accessibility of the ATFs for their target 
sites in the maspin promoter.
Methyltransferase and HDAC inhibitors interfere with two enzymatic mechanisms of 
repression: 5-aza-2′-dC inhibits DNA methyltransferase Dnmt1 enzyme (39, 41, 49), 
whereas SAHA promotes histone acetylation and weakens the histone-DNA interactions 
3Supplementary material for this article is available at Molecular Cancer Therapeutics (http://mct.aacrjournals.org/).
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(50). Synergy between methyltransferase and HDAC agents in reactivating silenced tumor 
suppressors has been previously reported by many groups (14, 22, 25, 51, 52). Our results 
further show that ATF expression highly amplifies the gene reactivation effect of chromatin 
remodeling drugs with different mechanisms of action. In contrast with chromatin 
remodeling drugs, which potentially alter many genes in the genome, the ATF is used as a 
sequence-specific regulator of tumor suppression expression. Our results agree with a report 
showing that overexpression of the p53 transcription factor in the p53-deficient MDA-
MB-231 cell line leads to a synergy with 5-aza-2′-dC in reactivation of the tumor suppressor 
maspin (13). We have found that, like natural transcription factors, ATFs can strongly 
synergize with both methyltransferase and HDAC inhibitors. Because ATFs can be designed 
for virtually any sequence in the human genome, the strategy presented in this article can be 
potentially applied for the reactivation of any epigenetically silenced promoter. Current ATF 
technology can generate ATF binding designed sequences with high specificity and 
selectivity in both in vitro binding assays and in reporter transactivation assays. Only a 
subset of ATFs designed against a given target promoter results in successful endogenous 
regulation (27), indicating that subtle aspects of the architecture of endogenous promoters 
may be key determinants for ATF-mediated regulation. Chromatin modifications could limit 
the binding of the ATFs in vivo by restricting ATF target site accessibility. This idea is 
supported by our observations, which show a gain of ATF-mediated regulation of silenced 
promoters only in the presence of chromatin remodeling drugs with ATFs having poor or no 
activity in the absence of remodeling-inducing compounds.
Importantly, we found that strong synergy between ATF/chromatin remodeling drugs was 
maintained in a concentration range of inhibitors below their IC50. Although more 
experiments need to be done to evaluate the applicability of our findings to experiments 
using tumor models in vivo, our work shows proof of concept of an exciting strategic 
approach in therapeutics, which uses ATFs to amplify the apoptotic response of anticancer 
agents with locus-targeted gene activation while minimizing the exposure/concentration of 
the drugs.
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ATFs designed to reactivate the maspin promoter. A, schematic representation of a 6ZF-
ATF. B, cytosine methylation status of maspin in MDA-MB-231 breast cancer cells. X axis, 
nucleotide position relative to the transcription start site; Y axis, percentage of methylation 
along the maspin promoter. The maspin proximal promoter region (−495 to +134) was 
originally reported by Zhang et al. (53). 5-Methylcytosine levels were obtained by sodium 
bisulfite genomic sequencing of the maspin promoter from genomic DNA of untransduced 
MDA-MB-231 cells. Transcription factor–binding sites were included [p53-binding sites 
(35) and ATF-binding sites (27)]. Red nucleotides indicate the methylated cytosines in the 
ATF-binding sites.
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ATFs synergize with chromatin remodeling drugs to reactivate maspin expression. A, real-
time quantification of maspin in untransduced MDA-MB-231 cells, cells retrovirally 
transduced with an empty retroviral vector (control), cells transduced with ATFs, and cells 
transduced with a control retrovirus lacking the ZF domains (pMXVP64SS). These samples 
were treated with 5-aza-2′-dC (1.0 μg/mL) or SAHA (0.5 μg/mL) or both inhibitors (same 
concentrations) using complete cell culture medium for the dilution of the drugs during 48 h 
in a 37°C, 5% CO2 incubator. Cells were collected, and the RNA was extracted, reverse 
transcribed, and processed for real-time maspin quantification. Real-time PCR data were 
analyzed using the comparative 2−ΔΔCT method and expressed as fold change in maspin 
mRNA expression normalized to GAPDH and relative to the vehicle-treated control (52). 
Differences between treatments were analyzed using ANOVA test and the post hoc Turkish 
test; critical level of significance was set up at P < 0.05. B, real-time expression analysis of 
maspin mRNA levels in the breast cancer cell lines MCF-12A, MDA-MB-468, and MDA-
MB-231. MDA-MB-231 cells were transduced with a control empty retroviral vector, with 
ATF-126, and with ATF-126 in the presence of 5-aza-2′-dC (1.0 μg/mL) and SAHA (0.5 μg/
mL). MCF-12A was used as a normalizing control. C, Western blot for the detection of 
maspin in the MCF-12A, MDA-MB-468, and MDA-MB-231 cell lines. MDA-MB-231 cells 
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were transduced with control vector or ATF-126 and treated with a combination of 5-aza-2′-
dC/SAHA (0.5 and 1 μg/mL, respectively).
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ATFs synergize with low concentrations of chromatin remodeling drugs to reactivate maspin 
mRNA expression. A and B, dose-effect plots assessing changes in maspin mRNA levels in 
cells treated with different concentrations of 5-aza-2′-dC and SAHA. Fold maspin mRNA 
levels were evaluated by real-time PCR using as a normalized control vehicle-treated cells. 
C, dose-effect plots assessing changes in maspin mRNA levels in cells transduced with 
different concentrations of ATF-126. D, mRNA expression changes of ATF directly 
correlate with changes on maspin mRNA levels, as evaluated by real-time PCR using 
primers specific for the ATF and maspin, respectively. Changes in mRNA expression of the 
ATF were generated, varying the amount of ATF-encoded DNA in the retroviral 
transduction. E, concentrations of ATF, 5-aza-2′-dC, and SAHA used in each combination 
tested. F, real-time expression analysis of maspin mRNA expression in ATF-transduced 
cells treated with specific combinations of 5-aza-2′-dC, SAHA, and both inhibitors, as 
indicated in E. MDA-MB-231 cells were transduced with ATF-126 (0.525 μg/mL; the Dm50 
for maspin expression) and treated with three different concentrations (Dm50, 1/2Dm50, 
and 1/3Dm50) of either 5-aza-2′-dC, SAHA, or both compounds. Cells were collected, and 
the RNA was extracted, reverse transcribed, and processed for real-time quantification of 
maspin. Using fold change in maspin, mRNA expression was calculated using the 
comparative 2−ΔΔC T method as described above (52). Differences between treatments were 
analyzed using ANOVA test and the post hoc Turkish test; critical level of significance was 
set up at P < 0.05.
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ATF-126 synergizes with 5-aza-2′-dC and SAHA in inhibiting tumor cell viability. A, 
ATF-126, 5-aza-2′-dC, and SAHA induce inhibition of tumor cell viability in a dose-
dependent manner. Dose-effect curves for cells transduced with different concentrations of 
the DNA of ATF-126 or treated with different concentrations of 5-aza-2′-dC and SAHA 
(Table 1).3 The effects of the ATFs and the chromatin remodeling drugs in inhibiting tumor 
cell viability were measured by the ability of metabolic active cells to reduce the tetrazolium 
salt XTT to orange-colored compounds of formazan. Dose-effect curves and median-effect 
plots were generated for each set of samples using the software package PharmToolsPro 
(28). B, CI for cells transduced with ATF-126 and treated with 5-aza-2′-dC (ATF-126 + 5-
aza-2′-dC), SAHA (ATF-126 + SAHA), and both inhibitors (ATF-126 + 5-aza-2′-dC + 
SAHA). Nontransduced cells were treated with both inhibitors (5-aza-2′-dC + SAHA). CI 
was calculated from the median-effect plots (31) to measure the synergistic action between 
ATF-126, 5-aza-2′-dC, and SAHA in the MDA-MB-231 breast cancer cell line. CI < 1 
defines a synergistic interaction, and CI > 1 defines an antagonistic drug interaction. The 
straight line at CI = 1 represents additive effects. C, inhibition of tumor cell viability on 
ATF-126 transduction and/or treatment with chromatin remodeling drugs. For single 
treatments, MDA-MB-231 cells were transduced with ATF-126 (0.525 μg/mL) or treated 
with 5-aza-2′-dC (3.75 μg/mL) and SAHA (1.32 μg/mL) for 48 h at 37°C and 5% CO2. The 
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same concentrations were used for the following combinations: 5-aza-2′-dC + SAHA, 
ATF-126 + 5-aza-2′-dC, ATF-126 + SAHA, and ATF-126 + 5-aza-2′-dC + SAHA. Cell 
viability was measured using the XTT assay, as described above. The data were analyzed 
using an ANOVA test and a post hoc Turkish test, as described in Materials and Methods. 
The asterisks indicate that the triple treatment decreased significantly tumor cell viability 
compared with all the other treatments tested. *, P = 0.05; **, P = 0.01; ***, P = 0.001.
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A putative model explaining the synergy between the ATF and the chromatin remodeling 
drugs in reactivating a methylated maspin promoter. A, the binding of ATF to the 
methylated promoter triggers a partial reactivation of the maspin gene. B, synergistic 
interaction between the ATFs and chromatin remodeling drugs. On treatment with 
chromatin remodeling drugs, changes in the chromatin structure facilitate the landing of 
ATF on the maspin promoter, which enhances the maspin reactivation.
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Table 1
CI values for single, double, and triple combinations of ATF-126, 5-aza-2′-dC, and SAHA
ATF/Drug (μg/mL) fa CI
ATF-126 SAHA 5-aza-2′-dC
0.075 0.13215 0.484 0.633
0.150 0.264 0.645 0.647
0.300 0.396 0.713 0.874
0.375 0.661 0.758 0.930
0.525 1.322 0.819 1.028
0.075 0.250 0.389 0.763
0.150 0.625 0.571 0.673
0.300 1.250 0.648 0.939
0.375 2.500 0.733 0.755
0.525 3.750 0.786 0.767
0.132 0.250 0.272 0.507
0.264 0.625 0.386 0.583
0.396 1.250 0.441 0.712
0.661 2.500 0.570 0.675
1.322 3.750 0.634 1.000
0.075 0.132 0.250 0.569 0.456
0.150 0.264 0.625 0.704 0.497
0.300 0.396 1.250 0.779 0.613
0.375 0.661 2.500 0.839 0.561
0.525 1.322 3.750 0.947 0.275
NOTE: Experimental dose combinations of ATF-126, SAHA, and 5-aza-2′-dC are indicated. MDA-MB-231 cells were transduced with ATF-126 
and treated with 5-aza-2′-CC or SAHA or both for 48 h. Cell viability was measured by using an XTT assay.
Abbreviation: fa, fraction of cells affected by the treatment (no viable cells).
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